Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...
The best way to beat persistent inflation is to invest in businesses unaffected by rising prices, like these four high-yield ...
Pfizer’s Talzenna in combi with Xtandi improves survival outcomes in metastatic castration resistant prostate cancer: New York Saturday, February 15, 2025, 11:00 Hrs [IST] Pfize ...
DexCom reported Q4 revenue of $1.11 billion, surpassing estimates. The company reaffirmed its 2025 outlook while analysts ...
The Centers for Medicare and Medicaid Services (CMS) and pharmaceutical drug manufacturers are gearing up for the second ...
Responses were similar among patients with estrogen patches and ARPIs compared to luteinizing hormone releasing hormone ...
Results from the company’s Talapro-2 trial saw a 38% reduction in the risk of death among HRR-mutated patients.
Pfizer's TALAPRO-2 study shows Talzenna + Xtandi significantly improves survival in mCRPC patients, with up to a 14-month OS ...
Updated data from the Phase III TALAPRO-2 trial show that the combination of Talzenna (talazoparib) and Xtandi (enzalutamide) significantly improves overall survival in patients with metastatic ...
Positve overall survival data could lead to a label expansion for Pfizer's combination to treat metastatic ...
Medpage Today on MSN5d
Adding Radioligand to Enzalutamide Boosts OS in Metastatic CRPCShe noted the survival benefit with the combination was achieved even though 38% of patients in the enzalutamide-alone arm ...
Patients with mCRPC taking LuPSMA had a median OS of 34 months vs 26 months with enzalutamide alone.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback